BrainsWay (BrainsWay) FCF Margin % : 22.51% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is BrainsWay FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BrainsWay's Free Cash Flow for the three months ended in Dec. 2023 was $2.03 Mil. BrainsWay's Revenue for the three months ended in Dec. 2023 was $9.03 Mil. Therefore, BrainsWay's FCF Margin % for the quarter that ended in Dec. 2023 was 22.51%.

As of today, BrainsWay's current FCF Yield % is -1.23%.

The historical rank and industry rank for BrainsWay's FCF Margin % or its related term are showing as below:

BRSYF' s FCF Margin % Range Over the Past 10 Years
Min: -156.48 Med: -35.48 Max: -3.47
Current: -3.68

During the past 11 years, the highest FCF Margin % of BrainsWay was -3.47%. The lowest was -156.48%. And the median was -35.48%.

BRSYF's FCF Margin % is ranked better than
54.72% of 826 companies
in the Medical Devices & Instruments industry
Industry Median: -7.29 vs BRSYF: -3.68

BrainsWay FCF Margin % Historical Data

The historical data trend for BrainsWay's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BrainsWay FCF Margin % Chart

BrainsWay Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-45.69

-17.71

-4.57

-35.91

-3.47

BrainsWay Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-37.18	-53.45	-6.41	10.14	22.51

Competitive Comparison of BrainsWay's FCF Margin %

For the Medical Devices subindustry, BrainsWay's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BrainsWay's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BrainsWay's FCF Margin % distribution charts can be found below:

* The bar in red indicates where BrainsWay's FCF Margin % falls into.

BrainsWay FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

BrainsWay's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-1.103	/	31.785
	=	-3.47 %

BrainsWay's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	2.032	/	9.029
	=	22.51 %

BrainsWay FCF Margin % Related Terms

Thank you for viewing the detailed overview of BrainsWay's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

BrainsWay (BrainsWay) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BrainsWay Ltd (OTCPK:BRSYF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BWAY:USA BWAY:Israel

Address

19 Hartum Street, 3rd Floor, Bynet Building, Har Hotzvim, Jerusalem, ISR, 9777518

Website

https://www.brainsway.com

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.